<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547258</url>
  </required_header>
  <id_info>
    <org_study_id>IRST204.01</org_study_id>
    <nct_id>NCT03547258</nct_id>
  </id_info>
  <brief_title>Italian Non-Interventional Study of FLT3 Mutated AML Patients</brief_title>
  <acronym>FLAM</acronym>
  <official_title>Italian Non-Interventional Study of FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study involving a retrospective and prospective collection of
      clinical and molecular data regarding patients with AML with FLT3+ mutations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study involving a retrospective and prospective collection of
      clinical and molecular data. Patients will follow their regular diagnostic and clinical
      practice. Thus, no additional procedure/blood withdrawal will be performed.

      The study will be conducted as follows:

        1. Retrospective phase: clinical and molecular data of AML patients with FLT3+ mutations
           detected at diagnosis or at any refractory/relapse state will be collected.

        2. Prospective phase: clinical and molecular data of each new FLT3+ AML patient identified
           in participating centers at diagnosis or at any refractory/relapse state will be
           collected prospectively. Every effort will be done to include all consecutive patients,
           in order to avoid selection bias.

      For patients with a mutation found at the time of disease relapse, any effort will be done to
      collect all the clinical and molecular information since the time of diagnosis.

      The Primary objective of this study is to analyze how FLT3 mutational status evolve during
      the management of the disease looking at the percentage of patients with no FLT3 mutations at
      diagnosis who relapse with a new FLT3 mutation detected, and the percentage of FLT3 positive
      AML patients that after having obtained a Complete Remission relapse with FLT3 negative.

      The secondary objective of the study is to investigate the association between different FLT3
      mutations and the clinical, molecular and biological information.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients FLT3 negative at diagnosis who relapse FLT3 positive;</measure>
    <time_frame>up to 24 months</time_frame>
    <description>description of how the FLT3 mutational status changes during the course and management of the disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of patients FLT3 positive at diagnosis who relapse FLT3 negative</measure>
    <time_frame>up to 24 months</time_frame>
    <description>description of how the FLT3 mutational status changes during the course and management of the disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective overall response rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the objective overall response rate (ORR) defined as the proportion of patients with a partial or response (CR, CRi, CRp) response, to initial treatment and in case of salvage;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>disease-free survival (DFS) after first CR and after CR2/CR3, if applicable, defined as the time since CR (or CR2 or CR3) to disease relapse or death for any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>overall survival (OS) defined as the time since date of diagnosis until death for any cause or the last available patient contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AML patients with specific types of FLT3 mutations</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Percentage of AML patients with specific types of FLT3 mutations, at initial diagnosis and at disease relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of specific FLT3 mutations in AML patients</measure>
    <time_frame>up to 24 months</time_frame>
    <description>distribution of specific FLT3 mutations in AML patients according to: age, WBC, LDH, cytogenetics, NPM1, CEBPA alterations, IDH1/2, tp53, DNMT3A, secondary vs de novo AML;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of the different methods used to evaluate (Minimal residual disease) MRD</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the frequency of the different methods used to evaluate MRD such as, wt1 ratio or the fusion transcript level by Reverse transcription polymerase chain reaction (RT-PCR); percentage of patients performing FLT3 ITD analysis by Next Generation Sequencing (NGS);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FLT3-ITD allelic ratio</measure>
    <time_frame>up to 24 months</time_frame>
    <description>FLT3-ITD allelic ratio defined as the ratio of the area under the curve of mutant and wild type alleles (mutant/totalFLT3) obtained after Fragment analysis for FLT3-ITD;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplantation percentage</measure>
    <time_frame>up to 24 months</time_frame>
    <description>percentage of FLT3 mutated AML patients undergoing transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of modifications in terms of quality of life (QoL) of patients with FLT3 mutated AML</measure>
    <time_frame>up to 24 months</time_frame>
    <description>scores for each patient and each scale as well as a summary QoL score will be computed according to the EORTC QLQ-C3 (quality of life questionnaire) manual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>retrospective collection of surrogate measures of QoL</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the surrogate measures of QoL , as the number and days of hospitalizations per patient, number of clinical visits per patient, number of access in Day Hospital and Emergency Care Units per patient, and the use of antalgic drugs and neuro-active drugs, will be expressed in terms of mean values per patient or through proportions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>AML</condition>
  <condition>FLT3-ITD Mutation</condition>
  <condition>FLT3-TKD Mutation</condition>
  <arm_group>
    <arm_group_label>AML patients</arm_group_label>
    <description>Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Clinical and Molecular data collection</intervention_name>
    <description>Clinical and Molecular data collection at diagnosis, during treatment and at each relapse</description>
    <arm_group_label>AML patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patient with FLT3 mutated AML documented at diagnosis or at the time of
        relapse/refractory state treated in the participating center. With regards to the
        retrospective collection, data from the eligible and acconsenting patients will be
        retrieved since 2012, that is, when the evaluation of FLT3 mutation was almost routine in
        the centers considered in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. AML patients

          2. Male or Female

          3. Aged â‰¥ 18 years

          4. FLT3 mutations (ITD or TKD) positive tests performed at diagnosis or at relapse.

          5. Participant is willing and able to give informed consent for participation in the
             study.

        Exclusion criteria:

        1. To be currently involved in experimental clinical protocol, or have been treated with
        experimental drugs are not exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Martinelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana Nanni</last_name>
    <phone>+390543739266</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Ospedali riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Olivieri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Bari - Ematologia</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Albano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  di Bologna - DIMES</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Papayannidis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Spedali di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Cattaneo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Romani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Mattei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ematologia - Azienda Ospedaliera &quot;Pugliese Ciaccio&quot; di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Martinelli, MD</last_name>
      <phone>0390543739100</phone>
      <email>giovanni.martinelli@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Maria Benedetta Giannini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Universitaria Arcispedale Sant'Anna</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Matteo Rigolin, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa sollievo della sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, DR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi di Lecce</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, DR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Musolino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Stefano Fracchiolla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Todisco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Vallisa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irccs Crob</name>
      <address>
        <city>Rionero In Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pellegrino Mustu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma - Ematologia e CTMO</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Roti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Ematologia, Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Lanza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Oliva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Mianulli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU San Giovannidi Dio e Ruggi - ematologia</name>
      <address>
        <city>Salerno</city>
        <state>SA</state>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmine Selleri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOC di Ematologia - AOU Senese</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bocchia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  di Torino - Ospedale San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Cilloni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU CittÃ  della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesta Audisio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Ordine Mauriziano Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Cignetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - UniversitÃ  di Udine</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Candoni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della caritÃ </name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monia Lunghi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Santa Maria della Misericordia - Ematologia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Paola Martelli, Prof.ssa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Italian observational study</keyword>
  <keyword>FLT3-ITD Mutation</keyword>
  <keyword>FLT3-TKD Mutation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

